Raymond James & Associates Viking Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 441,590 shares of VKTX stock, worth $15.6 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
441,590
Previous 308,446
43.17%
Holding current value
$15.6 Million
Previous $16.4 Million
70.99%
% of portfolio
0.02%
Previous 0.01%
Shares
25 transactions
Others Institutions Holding VKTX
# of Institutions
455Shares Held
67.9MCall Options Held
7.72MPut Options Held
3.31M-
Vanguard Group Inc Valley Forge, PA10.2MShares$359 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$213 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$133 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$115 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$111 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.71B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...